查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1941488

免疫療法藥物市場規模、佔有率和趨勢分析報告：按藥物類型、適應症、地區和細分市場預測（2026-2033 年）

Immunotherapy Drugs Market Size, Share & Trends Analysis Report By Drug Type (Monoclonal Antibodies, Immunomodulators, Vaccine), By Indication (Cancer, Infectious Diseases, Autoimmune Diseases), By Region, And Segment Forecasts, 2026 - 2033
出版日期: | 出版商: Grand View Research | 英文 100 Pages | 商品交期: 2-10個工作天內

價格

免疫療法藥物市場概覽

2025年全球免疫療法市場規模估計為2,857.3億美元，預計2033年將達到6,759.8億美元。

預計從2026年到2033年，該市場將以11.41%的複合年成長率成長。推動該市場成長的主要因素是全球慢性病發生率的上升。

全球慢性疾病負擔日益加重，包括癌症、自體免疫疾病和發炎性疾病，以及化療和放射線治療等傳統治療方法的限制日益凸顯，推動了免疫療法市場的發展。這些限制加速了免疫療法的轉變，免疫療法具有標靶作用機制，能夠改善患者預後。例如，世界衛生組織（世衛組織）2025年2月發布的報告顯示，2020年全球癌症死亡人數約1,000萬，約佔全球死亡總數的六分之一。其中，乳癌病例226萬例，肺癌病例221萬例，大腸癌病例193萬例，肺癌死亡人數達180萬人。世衛組織也估計，每年約有40萬例兒童癌症病例，並指出低收入和中低收入國家30%的癌症病例與感染疾病有關。這些因素進一步刺激了對先進免疫療法的需求。

技術進步和強勁的研究活動在推動免疫療法市場發展方面發揮關鍵作用。免疫腫瘤學領域，特別是細胞療法（如免疫查核點抑制劑、單株抗體和CAR-T療法）的顯著進展，徹底改變了癌症治療的模式。這些治療方法已在多種固態腫瘤和骨髓惡性腫瘤中展現出高效性，從而拓展了其臨床適應症。製藥和生技公司正大力投資研發，以提高療效、減少副作用並開發下一代免疫療法。策略聯盟、併購也加速了創新和產品線的擴展。此外，主要市場有利的法規結構、加速核准程序和孤兒藥認定，也促進了新型免疫療法的快速商業化，顯著推動了市場成長。

除了腫瘤領域，免疫療法市場也受惠於全球應用範圍的擴大和醫療基礎設施的改善，從而拓展了整體市場潛力。自體免疫、感染疾病和罕見遺傳疾病的免疫療法研究進展正在推動其更廣泛的臨床應用。在已開發地區，完善的醫保體系、高額的醫療支出以及先進的診斷設施促進了免疫療法的常規應用。同時，新興經濟體由於醫療體系的改善、醫療旅遊的興起以及政府旨在加強癌症治療的舉措，也實現了穩步成長。意識提升，以及生技藥品成本效益的逐步改善，進一步推動了免疫療法的應用。這些相互關聯的因素共同支撐著全球免疫療法市場的長期成長前景和持續創新。

目錄

第1章調查方法和範圍

第2章執行摘要

第3章 免疫療法藥物市場變數、趨勢與範圍

  • 市場概況/產品線展望
  • 市場規模和成長前景
  • 市場動態
  • 免疫療法藥物市場分析工具
    • 波特分析
    • PESTEL 分析

第4章：免疫療法藥物市場：按藥物類型分類的估算和趨勢分析

  • 按藥物類型分類的市場佔有率（2025 年和 2033 年）
  • 市場規模、預測與趨勢分析（按藥物類型分類，2021-2033 年）
  • 單株抗體
  • 免疫調節劑
  • 疫苗
  • 其他

第5章：免疫療法藥物市場：依適應症分類的估算與趨勢分析

  • 按適應症分類的市場佔有率（2025 年和 2033 年）
  • 市場規模、預測與趨勢分析（按指標，2021-2033 年）
  • 癌症
  • 自體免疫疾病
  • 感染疾病
  • 其他

第6章：免疫療法藥物市場：區域、預測與趨勢分析

  • 2025年及2033年區域市佔率分析
  • 區域市場概覽
  • 市場規模及預測趨勢分析，2021-2033年
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 丹麥
    • 瑞典
    • 挪威
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 泰國
    • 韓國
    • 澳洲
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中東和非洲
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 科威特

第7章 競爭情勢

  • 參與公司概況
  • 企業市場分析
  • 公司分類
  • 策略規劃
  • 公司簡介/列表
    • Amgen Inc.
    • Novartis AG
    • AbbVie Inc.
    • Pfizer Inc.
    • F. Hoffmann-La Roche Ltd
    • Johnson & Johnson Services, Inc.
    • AstraZeneca
    • GSK plc.
    • Sanofi
    • Bayer AG
Product Code: GVR-4-68039-961-5

Immunotherapy Drugs Market Summary

The global immunotherapy drugs market size was estimated at USD 285.73 billion in 2025 and is expected to reach USD 675.98 billion by 2033, growing at a CAGR of 11.41% from 2026 to 2033. This market is primarily driven by the rising incidence of chronic diseases globally.

This market was driven by the rising global burden of cancer and chronic diseases, including autoimmune and inflammatory disorders, alongside the growing limitations of conventional treatments such as chemotherapy and radiation therapy. These constraints had accelerated the shift toward immunotherapy because of its targeted mechanism of action and improved patient outcomes. For instance, February 2025, the World Health Organization reported that cancer was responsible for nearly 10 million deaths in 2020, accounting for almost one in six deaths globally. Breast cancer recorded 2.26 million cases, lung cancer 2.21 million, and colorectal cancer 1.93 million, while lung cancer caused 1.80 million deaths. The organization also estimated around 400,000 childhood cancer cases annually and noted that 30 percent of cancers in low and lower middle income countries were infection related, reinforcing demand for advanced immunotherapies.

Technological advancements and robust research activity play a critical role in driving the immunotherapy drugs market forward. Significant progress in immuno-oncology, particularly in immune checkpoint inhibitors, monoclonal antibodies, and cell-based therapies such as CAR-T, has transformed cancer treatment paradigms. These therapies have demonstrated strong efficacy across multiple solid tumors and hematological malignancies, leading to expanding clinical indications. Pharmaceutical and biotechnology companies are investing heavily in research and development to improve therapeutic effectiveness, reduce adverse effects, and develop next-generation immunotherapies. Strategic collaborations, mergers, and acquisitions are also accelerating innovation and pipeline expansion. Moreover, favorable regulatory frameworks, fast-track approvals, and orphan drug designations in major markets are enabling faster commercialization of novel immunotherapy drugs, thereby contributing significantly to market growth.

Beyond oncology, the immunotherapy drugs market was supported by expanding applications and improving healthcare infrastructure worldwide, which broadened overall market potential. Immunotherapies were increasingly explored for autoimmune diseases, infectious diseases, and rare genetic disorders, enabling wider clinical adoption. In developed regions, strong reimbursement systems, higher healthcare spending, and access to advanced diagnostic facilities facilitated routine use of immunotherapy drugs. At the same time, emerging economies experienced steady growth due to improvements in healthcare systems, rising medical tourism, and government initiatives aimed at strengthening cancer care delivery. Growing awareness among patients and healthcare providers, coupled with gradual improvements in the affordability of biologic therapies, further supported uptake. Together, these interconnected factors sustained long term growth prospects and continued innovation in the global immunotherapy drugs market.

Global Immunotherapy Drugs Market Report Segmentation

This report forecasts revenue growth and provides an analysis of the latest trends in each of the sub-segments from 2021 to 2033. For this report, Grand View Research has segmented the global immunotherapy drugs market report based on drug type, indication, and region:

  • Drug Type Outlook (Revenue, USD Million, 2021 - 2033)
  • Monoclonal Antibodies
  • Immunomodulator
  • Vaccine
  • Others
  • Indication Outlook (Revenue, USD Million, 2021 - 2033)
  • Cancer
  • Autoimmune Diseases
  • Infectious Diseases
  • Others
  • Regional Outlook (Revenue, USD Million, 2021 - 2033)
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
    • Denmark
    • Sweden
    • Norway
  • Asia Pacific
    • Japan
    • China
    • India
    • Thailand
    • South Korea
    • Australia
  • Latin America
    • Brazil
    • Argentina
  • Middle East and Africa (MEA)
    • South Africa
    • Saudi Arabia
    • UAE
    • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Market Definitions
  • 1.3. Research Methodology
    • 1.3.1. Information Procurement
    • 1.3.2. Information or Data Analysis
    • 1.3.3. Market Formulation & Data Visualization
    • 1.3.4. Data Validation & Publishing
  • 1.4. Research Scope and Assumptions
    • 1.4.1. List of Data Sources

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. Immunotherapy Drugs Market Variables, Trends, & Scope

  • 3.1. Market Introduction/Lineage Outlook
  • 3.2. Market Size and Growth Prospects (USD Million)
  • 3.3. Market Dynamics
    • 3.3.1. Market Drivers Analysis
    • 3.3.2. Market Restraints Analysis
  • 3.4. Immunotherapy Drugs Market Analysis Tools
    • 3.4.1. Porter's Analysis
      • 3.4.1.1. Bargaining power of the suppliers
      • 3.4.1.2. Bargaining power of the buyers
      • 3.4.1.3. Threats of substitution
      • 3.4.1.4. Threats from new entrants
      • 3.4.1.5. Competitive rivalry
    • 3.4.2. PESTEL Analysis
      • 3.4.2.1. Political landscape
      • 3.4.2.2. Economic and Social landscape.
      • 3.4.2.3. Technological landscape
      • 3.4.2.4. Environmental landscape
      • 3.4.2.5. Legal landscape

Chapter 4. Immunotherapy Drugs Market: Drug Type Estimates & Trend Analysis

  • 4.1. Drug Type Market Share, 2025 & 2033
  • 4.2. Drug Type Segment Dashboard
  • 4.3. Market Size & Forecasts and Trend Analysis, by Drug Type, 2021 to 2033 (USD Million)
  • 4.4. Monoclonal Antibodies
    • 4.4.1. Monoclonal Antibodies Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.5. Immunomodulator
    • 4.5.1. Immunomodulator Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.6. Vaccine
    • 4.6.1. Vaccine Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.7. Others
    • 4.7.1. Others Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 5. Immunotherapy Drugs Market: Indication Estimates & Trend Analysis

  • 5.1. Indication Market Share, 2025 & 2033
  • 5.2. Indication Segment Dashboard
  • 5.3. Market Size & Forecasts and Trend Analysis, by Drug Type, 2021 to 2033 (USD Million)
  • 5.4. Cancer
    • 5.4.1. Cancer Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.5. Autoimmune Diseases
    • 5.5.1. Autoimmune Diseases Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.6. Infectious Diseases
    • 5.6.1. Infectious Diseases Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.7. Others
    • 5.7.1. Others Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 6. Immunotherapy Drugs Market: Regional Estimates & Trend Analysis

  • 6.1. Regional Market Share Analysis, 2025 & 2033
  • 6.2. Regional Market Dashboard
  • 6.3. Market Size & Forecasts Trend Analysis, 2021 to 2033:
  • 6.4. North America
    • 6.4.1. North America Immunotherapy Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.4.2. U.S.
      • 6.4.2.1. Key Country Dynamics
      • 6.4.2.2. Regulatory Framework
      • 6.4.2.3. Competitive Insights
      • 6.4.2.4. U.S. Immunotherapy Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.4.3. Canada
      • 6.4.3.1. Key Country Dynamics
      • 6.4.3.2. Regulatory Framework
      • 6.4.3.3. Competitive Insights
      • 6.4.3.4. Canada Immunotherapy Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.4.4. Mexico
      • 6.4.4.1. Key Country Dynamics
      • 6.4.4.2. Regulatory Framework
      • 6.4.4.3. Competitive Insights
      • 6.4.4.4. Mexico Immunotherapy Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.5. Europe
    • 6.5.1. Europe Immunotherapy Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.2. UK
      • 6.5.2.1. Key Country Dynamics
      • 6.5.2.2. Regulatory Framework
      • 6.5.2.3. Competitive Insights
      • 6.5.2.4. UK Immunotherapy Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.3. Germany
      • 6.5.3.1. Key Country Dynamics
      • 6.5.3.2. Regulatory Framework
      • 6.5.3.3. Competitive Insights
      • 6.5.3.4. Germany Immunotherapy Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.4. France
      • 6.5.4.1. Key Country Dynamics
      • 6.5.4.2. Regulatory Framework
      • 6.5.4.3. Competitive Insights
      • 6.5.4.4. France Immunotherapy Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.5. Italy
      • 6.5.5.1. Key Country Dynamics
      • 6.5.5.2. Regulatory Framework
      • 6.5.5.3. Competitive Insights
      • 6.5.5.4. Italy Immunotherapy Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.6. Spain
      • 6.5.6.1. Key Country Dynamics
      • 6.5.6.2. Regulatory Framework
      • 6.5.6.3. Competitive Insights
      • 6.5.6.4. Spain Immunotherapy Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.7. Denmark
      • 6.5.7.1. Key Country Dynamics
      • 6.5.7.2. Regulatory Framework
      • 6.5.7.3. Competitive Insights
      • 6.5.7.4. Denmark Immunotherapy Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.8. Sweden
      • 6.5.8.1. Key Country Dynamics
      • 6.5.8.2. Regulatory Framework
      • 6.5.8.3. Competitive Insights
      • 6.5.8.4. Sweden Immunotherapy Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.9. Norway
      • 6.5.9.1. Key Country Dynamics
      • 6.5.9.2. Regulatory Framework
      • 6.5.9.3. Competitive Insights
      • 6.5.9.4. Norway Immunotherapy Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.6. Asia Pacific
    • 6.6.1. Asia Pacific Immunotherapy Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.6.2. Japan
      • 6.6.2.1. Key Country Dynamics
      • 6.6.2.2. Regulatory Framework
      • 6.6.2.3. Competitive Insights
      • 6.6.2.4. Japan Immunotherapy Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.6.3. China
      • 6.6.3.1. Key Country Dynamics
      • 6.6.3.2. Regulatory Framework
      • 6.6.3.3. Competitive Insights
      • 6.6.3.4. China Immunotherapy Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.6.4. India
      • 6.6.4.1. Key Country Dynamics
      • 6.6.4.2. Regulatory Framework
      • 6.6.4.3. Competitive Insights
      • 6.6.4.4. India Immunotherapy Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.6.5. Thailand
      • 6.6.5.1. Key Country Dynamics
      • 6.6.5.2. Regulatory Framework
      • 6.6.5.3. Competitive Insights
      • 6.6.5.4. Thailand Immunotherapy Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.6.6. South Korea
      • 6.6.6.1. Key Country Dynamics
      • 6.6.6.2. Regulatory Framework
      • 6.6.6.3. Competitive Insights
      • 6.6.6.4. South Korea Immunotherapy Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.6.7. Australia
      • 6.6.7.1. Key Country Dynamics
      • 6.6.7.2. Regulatory Framework
      • 6.6.7.3. Competitive Insights
      • 6.6.7.4. Australia Immunotherapy Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.7. Latin America
    • 6.7.1. Latin America Immunotherapy Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.7.2. Brazil
      • 6.7.2.1. Key Country Dynamics
      • 6.7.2.2. Regulatory Framework
      • 6.7.2.3. Competitive Insights
      • 6.7.2.4. Brazil Immunotherapy Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.7.3. Argentina
      • 6.7.3.1. Key Country Dynamics
      • 6.7.3.2. Regulatory Framework
      • 6.7.3.3. Competitive Insights
      • 6.7.3.4. Argentina Immunotherapy Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.8. Middle East and Africa
    • 6.8.1. Middle East and Africa Immunotherapy Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.8.2. South Africa
      • 6.8.2.1. Key Country Dynamics
      • 6.8.2.2. Regulatory Framework
      • 6.8.2.3. Competitive Insights
      • 6.8.2.4. South Africa Immunotherapy Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.8.3. Saudi Arabia
      • 6.8.3.1. Key Country Dynamics
      • 6.8.3.2. Regulatory Framework
      • 6.8.3.3. Competitive Insights
      • 6.8.3.4. Saudi Arabia Immunotherapy Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.8.4. UAE
      • 6.8.4.1. Key Country Dynamics
      • 6.8.4.2. Regulatory Framework
      • 6.8.4.3. Competitive Insights
      • 6.8.4.4. UAE Immunotherapy Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.8.5. Kuwait
      • 6.8.5.1. Key Country Dynamics
      • 6.8.5.2. Regulatory Framework
      • 6.8.5.3. Competitive Insights
      • 6.8.5.4. Kuwait Immunotherapy Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Participant Overview
  • 7.2. Company Market Position Analysis
  • 7.3. Company Categorization
  • 7.4. Strategy Mapping
  • 7.5. Company Profiles/Listing
    • 7.5.1. Amgen Inc.
      • 7.5.1.1. Participant's Overview
      • 7.5.1.2. Financial Performance
      • 7.5.1.3. Product Benchmarking
      • 7.5.1.4. Recent Developments/ Strategic Initiatives
    • 7.5.2. Novartis AG
      • 7.5.2.1. Participant's Overview
      • 7.5.2.2. Financial Performance
      • 7.5.2.3. Product Benchmarking
      • 7.5.2.4. Recent Developments/ Strategic Initiatives
    • 7.5.3. AbbVie Inc.
      • 7.5.3.1. Participant's Overview
      • 7.5.3.2. Financial Performance
      • 7.5.3.3. Product Benchmarking
      • 7.5.3.4. Recent Developments/ Strategic Initiatives
    • 7.5.4. Pfizer Inc.
      • 7.5.4.1. Participant's Overview
      • 7.5.4.2. Financial Performance
      • 7.5.4.3. Product Benchmarking
      • 7.5.4.4. Recent Developments/ Strategic Initiatives
    • 7.5.5. F. Hoffmann-La Roche Ltd
      • 7.5.5.1. Participant's Overview
      • 7.5.5.2. Financial Performance
      • 7.5.5.3. Product Benchmarking
      • 7.5.5.4. Recent Developments/ Strategic Initiatives
    • 7.5.6. Johnson & Johnson Services, Inc.
      • 7.5.6.1. Participant's Overview
      • 7.5.6.2. Financial Performance
      • 7.5.6.3. Product Benchmarking
      • 7.5.6.4. Recent Developments/ Strategic Initiatives
    • 7.5.7. AstraZeneca
      • 7.5.7.1. Participant's Overview
      • 7.5.7.2. Financial Performance
      • 7.5.7.3. Product Benchmarking
      • 7.5.7.4. Recent Developments/ Strategic Initiatives
    • 7.5.8. GSK plc.
      • 7.5.8.1. Participant's Overview
      • 7.5.8.2. Financial Performance
      • 7.5.8.3. Product Benchmarking
      • 7.5.8.4. Recent Developments/ Strategic Initiatives
    • 7.5.9. Sanofi
      • 7.5.9.1. Participant's Overview
      • 7.5.9.2. Financial Performance
      • 7.5.9.3. Product Benchmarking
      • 7.5.9.4. Recent Developments/ Strategic Initiatives
    • 7.5.10. Bayer AG
      • 7.5.10.1. Participant's Overview
      • 7.5.10.2. Financial Performance
      • 7.5.10.3. Product Benchmarking
      • 7.5.10.4. Recent Developments/ Strategic Initiatives

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of abbreviations
  • Table 3 Global Immunotherapy Drugs Market, by Region, 2021 - 2033 (USD Million)
  • Table 4 Global Immunotherapy Drugs Market, by Drug Type, 2021 - 2033 (USD Million)
  • Table 5 Global Immunotherapy Drugs Market, by Indication, 2021 - 2033 (USD Million)
  • Table 6 North America Immunotherapy Drugs Market, by Country, 2021 - 2033 (USD Million)
  • Table 7 North America Immunotherapy Drugs Market, by Drug Type, 2021 - 2033 (USD Million)
  • Table 8 North America Immunotherapy Drugs Market, by Indication, 2021 - 2033 (USD Million)
  • Table 9 U.S. Immunotherapy Drugs Market, by Drug Type, 2021 - 2033 (USD Million)
  • Table 10 U.S. Immunotherapy Drugs Market, by Indication, 2021 - 2033 (USD Million)
  • Table 11 Canada Immunotherapy Drugs Market, by Drug Type, 2021 - 2033 (USD Million)
  • Table 12 Canada Immunotherapy Drugs Market, by Indication, 2021 - 2033 (USD Million)
  • Table 13 Mexico Immunotherapy Drugs Market, by Drug Type, 2021 - 2033 (USD Million)
  • Table 14 Mexico Immunotherapy Drugs Market, by Indication, 2021 - 2033 (USD Million)
  • Table 15 Europe Immunotherapy Drugs Market, by Country, 2021 - 2033 (USD Million)
  • Table 16 Europe Immunotherapy Drugs Market, by Drug Type, 2021 - 2033 (USD Million)
  • Table 17 Europe Immunotherapy Drugs Market, by Indication, 2021 - 2033 (USD Million)
  • Table 18 Germany Immunotherapy Drugs Market, by Drug Type, 2021 - 2033 (USD Million)
  • Table 19 Germany Immunotherapy Drugs Market, by Indication, 2021 - 2033 (USD Million)
  • Table 20 UK Immunotherapy Drugs Market, by Drug Type, 2021 - 2033 (USD Million)
  • Table 21 UK Immunotherapy Drugs Market, by Indication, 2021 - 2033 (USD Million)
  • Table 22 France Immunotherapy Drugs Market, by Drug Type, 2021 - 2033 (USD Million)
  • Table 23 France Immunotherapy Drugs Market, by Indication, 2021 - 2033 (USD Million)
  • Table 24 Italy Immunotherapy Drugs Market, by Drug Type, 2021 - 2033 (USD Million)
  • Table 25 Italy Immunotherapy Drugs Market, by Indication, 2021 - 2033 (USD Million)
  • Table 26 Spain Immunotherapy Drugs Market, by Drug Type, 2021 - 2033 (USD Million)
  • Table 27 Spain Immunotherapy Drugs Market, by Indication, 2021 - 2033 (USD Million)
  • Table 28 Sweden Immunotherapy Drugs Market, by Drug Type, 2021 - 2033 (USD Million)
  • Table 29 Sweden Immunotherapy Drugs Market, by Indication, 2021 - 2033 (USD Million)
  • Table 30 Denmark Immunotherapy Drugs Market, by Drug Type, 2021 - 2033 (USD Million)
  • Table 31 Denmark Immunotherapy Drugs Market, by Indication, 2021 - 2033 (USD Million)
  • Table 32 Norway Immunotherapy Drugs Market, by Drug Type, 2021 - 2033 (USD Million)
  • Table 33 Norway Immunotherapy Drugs Market, by Indication, 2021 - 2033 (USD Million)
  • Table 34 Asia Pacific Immunotherapy Drugs Market, by Country, 2021 - 2033 (USD Million)
  • Table 35 Asia Pacific Immunotherapy Drugs Market, by Drug Type, 2021 - 2033 (USD Million)
  • Table 36 Asia Pacific Immunotherapy Drugs Market, by Indication, 2021 - 2033 (USD Million)
  • Table 37 China Immunotherapy Drugs Market, by Drug Type, 2021 - 2033 (USD Million)
  • Table 38 China Immunotherapy Drugs Market, by Indication, 2021 - 2033 (USD Million)
  • Table 39 Japan Immunotherapy Drugs Market, by Drug Type, 2021 - 2033 (USD Million)
  • Table 40 Japan Immunotherapy Drugs Market, by Indication, 2021 - 2033 (USD Million)
  • Table 41 India Immunotherapy Drugs Market, by Drug Type, 2021 - 2033 (USD Million)
  • Table 42 India Immunotherapy Drugs Market, by Indication, 2021 - 2033 (USD Million)
  • Table 43 South Korea Immunotherapy Drugs Market, by Drug Type, 2021 - 2033 (USD Million)
  • Table 44 South Korea Immunotherapy Drugs Market, by Indication, 2021 - 2033 (USD Million)
  • Table 45 Australia Immunotherapy Drugs Market, by Drug Type, 2021 - 2033 (USD Million)
  • Table 46 Australia Immunotherapy Drugs Market, by Indication, 2021 - 2033 (USD Million)
  • Table 47 Thailand Immunotherapy Drugs Market, by Drug Type, 2021 - 2033 (USD Million)
  • Table 48 Thailand Immunotherapy Drugs Market, by Indication, 2021 - 2033 (USD Million)
  • Table 49 Latin America Immunotherapy Drugs Market, by Country, 2021 - 2033 (USD Million)
  • Table 50 Latin America Immunotherapy Drugs Market, by Drug Type, 2021 - 2033 (USD Million)
  • Table 51 Latin America Immunotherapy Drugs Market, by Indication, 2021 - 2033 (USD Million)
  • Table 52 Brazil Immunotherapy Drugs Market, by Drug Type, 2021 - 2033 (USD Million)
  • Table 53 Brazil Immunotherapy Drugs Market, by Indication, 2021 - 2033 (USD Million)
  • Table 54 Argentina Immunotherapy Drugs Market, by Drug Type, 2021 - 2033 (USD Million)
  • Table 55 Argentina Immunotherapy Drugs Market, by Indication, 2021 - 2033 (USD Million)
  • Table 56 Middle East & Africa Immunotherapy Drugs Market, by Country, 2021 - 2033 (USD Million)
  • Table 57 Middle East & Africa Immunotherapy Drugs Market, by Drug Type, 2021 - 2033 (USD Million)
  • Table 58 Middle East & Africa Immunotherapy Drugs Market, by Indication, 2021 - 2033 (USD Million)
  • Table 59 South Africa Immunotherapy Drugs Market, by Drug Type, 2021 - 2033 (USD Million)
  • Table 60 South Africa Immunotherapy Drugs Market, by Indication, 2021 - 2033 (USD Million)
  • Table 61 Saudi Arabia Immunotherapy Drugs Market, by Drug Type, 2021 - 2033 (USD Million)
  • Table 62 Saudi Arabia Immunotherapy Drugs Market, by Indication, 2021 - 2033 (USD Million)
  • Table 63 UAE Immunotherapy Drugs Market, by Drug Type, 2021 - 2033 (USD Million)
  • Table 64 UAE Immunotherapy Drugs Market, by Indication, 2021 - 2033 (USD Million)
  • Table 65 Kuwait Immunotherapy Drugs Market, by Drug Type, 2021 - 2033 (USD Million)
  • Table 66 Kuwait Immunotherapy Drugs Market, by Indication, 2021 - 2033 (USD Million)

List of Figures

  • Fig. 1 Immunotherapy drugs market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 Market formulation & validation
  • Fig. 8 Market snapshot
  • Fig. 9 Segment outlook (USD Million)
  • Fig. 10 Competitive landscape
  • Fig. 11 Immunotherapy drugs market dynamics
  • Fig. 12 Immunotherapy drugs market: Porter's five forces analysis
  • Fig. 13 Immunotherapy drugs market: PESTLE analysis
  • Fig. 14 Immunotherapy drugs market: Drug type segment dashboard
  • Fig. 15 Immunotherapy drugs market: Drug type market share analysis, 2025 & 2033
  • Fig. 16 Monoclonal antibodies market, 2021 - 2033 (USD Million)
  • Fig. 17 Immunomodulator market, 2021 - 2033 (USD Million)
  • Fig. 18 Vaccine market, 2021 - 2033 (USD Million)
  • Fig. 19 Others market, 2021 - 2033 (USD Million)
  • Fig. 20 Immunotherapy drugs market: Indication segment dashboard
  • Fig. 21 Immunotherapy drugs market: Indication market share analysis, 2025 & 2033
  • Fig. 22 Cancer market, 2021 - 2033 (USD Million)
  • Fig. 23 Autoimmune diseases market, 2021 - 2033 (USD Million)
  • Fig. 24 Infectious diseases market, 2021 - 2033 (USD Million)
  • Fig. 25 Others market, 2021 - 2033 (USD Million)
  • Fig. 26 Immunotherapy drugs market revenue, by region
  • Fig. 27 Regional marketplace: Key takeaways
  • Fig. 28 North America immunotherapy drugs market, 2021 - 2033 (USD Million)
  • Fig. 29 U.S. country dynamics
  • Fig. 30 U.S. immunotherapy drugs market, 2021 - 2033 (USD Million)
  • Fig. 31 Canada country dynamics
  • Fig. 32 Canada immunotherapy drugs market, 2021 - 2033 (USD Million)
  • Fig. 33 Mexico country dynamics
  • Fig. 34 Mexico immunotherapy drugs market, 2021 - 2033 (USD Million)
  • Fig. 35 Europe immunotherapy drugs market, 2021 - 2033 (USD Million)
  • Fig. 36 UK country dynamics
  • Fig. 37 UK immunotherapy drugs market, 2021 - 2033 (USD Million)
  • Fig. 38 Germany country dynamics
  • Fig. 39 Germany immunotherapy drugs market, 2021 - 2033 (USD Million)
  • Fig. 40 France country dynamics
  • Fig. 41 France immunotherapy drugs market, 2021 - 2033 (USD Million)
  • Fig. 42 Italy country dynamics
  • Fig. 43 Italy immunotherapy drugs market, 2021 - 2033 (USD Million)
  • Fig. 44 Spain country dynamics
  • Fig. 45 Spain immunotherapy drugs market, 2021 - 2033 (USD Million)
  • Fig. 46 Denmark country dynamics
  • Fig. 47 Denmark immunotherapy drugs market, 2021 - 2033 (USD Million)
  • Fig. 48 Sweden country dynamics
  • Fig. 49 Sweden immunotherapy drugs market, 2021 - 2033 (USD Million)
  • Fig. 50 Norway country dynamics
  • Fig. 51 Norway immunotherapy drugs market, 2021 - 2033 (USD Million)
  • Fig. 52 Asia Pacific immunotherapy drugs market, 2021 - 2033 (USD Million)
  • Fig. 53 Japan country dynamics
  • Fig. 54 Japan immunotherapy drugs market, 2021 - 2033 (USD Million)
  • Fig. 55 China country dynamics
  • Fig. 56 China immunotherapy drugs market, 2021 - 2033 (USD Million)
  • Fig. 57 India country dynamics
  • Fig. 58 India immunotherapy drugs market, 2021 - 2033 (USD Million)
  • Fig. 59 Thailand country dynamics
  • Fig. 60 Thailand immunotherapy drugs market, 2021 - 2033 (USD Million)
  • Fig. 61 South Korea country dynamics
  • Fig. 62 South Korea immunotherapy drugs market, 2021 - 2033 (USD Million)
  • Fig. 63 Australia country dynamics
  • Fig. 64 Australia immunotherapy drugs market, 2021 - 2033 (USD Million)
  • Fig. 65 Latin America immunotherapy drugs market, 2021 - 2033 (USD Million)
  • Fig. 66 Brazil country dynamics
  • Fig. 67 Brazil immunotherapy drugs market, 2021 - 2033 (USD Million)
  • Fig. 68 Argentina country dynamics
  • Fig. 69 Argentina immunotherapy drugs market, 2021 - 2033 (USD Million
  • Fig. 70 MEA immunotherapy drugs market, 2021 - 2033 (USD Million)
  • Fig. 71 South Africa country dynamics
  • Fig. 72 South Africa immunotherapy drugs market, 2021 - 2033 (USD Million)
  • Fig. 73 Saudi Arabia country dynamics
  • Fig. 74 Saudi Arabia immunotherapy drugs market, 2021 - 2033 (USD Million)
  • Fig. 75 UAE country dynamics
  • Fig. 76 UAE immunotherapy drugs market, 2021 - 2033 (USD Million)
  • Fig. 77 Kuwait country dynamics
  • Fig. 78 Kuwait immunotherapy drugs market, 2021 - 2033 (USD Million)
  • Fig. 79 Company categorization
  • Fig. 80 Company market position analysis
  • Fig. 81 Strategic framework